human monoclonal antibody targeting human sclerostin | |
---|---|
Trade Name | |
Orphan Indication | Osteogenesis imperfecta |
USA Market Approval | USA |
USA Designation Date | 2016-02-29 00:00:00 |
Sponsor | Mereo Biopharma 3 Limited;1 Cavendish Place, 4th Floor;London |
Related Access Program
Agios Pharmaceuticals, Inc. – Acute Myeloid Leukemia
Novartis Pharmaceuticals – FLT3-mutated Acute Myeloid Leukemia
AbbVie – Acute Myeloid Leukemia (AML)
University of California, San Francisco – Acute Myeloid Leukemia
Emory University – Acute Myeloid Leukemia
British Columbia Cancer Agency – Thyroid Cancer, Medullary
Novartis Pharmaceuticals – Acute Myeloid Leukemia (AML) With
Beijing Cancer Hospital – Thyroid Nodules
Alnylam Pharmaceuticals – Amyloidosis, Hereditary
Alnylam Pharmaceuticals – TTR-mediated Amyloidosis
Astellas Pharma Global Development, Inc. – Acute Myeloid Leukemia (AML)